US 12,258,367 B2
Glucoside derivative that acts as SGLT1 inhibitor and application thereof
Yi Li, Shanghai (CN); Tao Yu, Shanghai (CN); Qinghua Mao, Shanghai (CN); Chengde Wu, Shanghai (CN); and Shuhui Chen, Shanghai (CN)
Assigned to MEDSHINE DISCOVERY INC., Nanjing (CN)
Appl. No. 17/599,308
Filed by MEDSHINE DISCOVERY INC., Jiangsu (CN)
PCT Filed Mar. 30, 2020, PCT No. PCT/CN2020/082007
§ 371(c)(1), (2) Date Sep. 28, 2021,
PCT Pub. No. WO2020/200153, PCT Pub. Date Oct. 8, 2020.
Claims priority of application No. 201910251853.5 (CN), filed on Mar. 29, 2019; application No. 201911104949.5 (CN), filed on Nov. 13, 2019; and application No. 202010105251.1 (CN), filed on Feb. 20, 2020.
Prior Publication US 2022/0153772 A1, May 19, 2022
Int. Cl. C07H 15/26 (2006.01); A61P 3/04 (2006.01); A61P 3/10 (2006.01)
CPC C07H 15/26 (2013.01) [A61P 3/04 (2018.01); A61P 3/10 (2018.01)] 17 Claims
 
1. A compound represented by formula (II), or a stereoisomer, a tautomer, or a pharmaceutically acceptable salt thereof,

OG Complex Work Unit Chemistry
wherein
R1 is selected from H, F, Cl, Br, I, OH, NH2, CN, C1-6 alkyl and C1-6 alkoxy, wherein the C1-6 alkyl and C1-6 alkoxy are optionally substituted with 1, 2, or 3 Ra;
R2 is selected from F, Cl, Br, I, OH, NH2 and C1-3 alkylamino;
R3, R4 and R5 are each independently selected from H, F, Cl, Br, I, OH, NH2, CN, and C1-3 alkyl optionally substituted with 1, 2, or 3 Rb;
L is selected from single bond, —O—, —S—, —C(Rc)2—, and —N(Rd)—;
m is selected from 0, 1, and 2;
n is selected from 1, 2, and 3;
Ra, Rb and Rc are each independently selected from F, Cl, Br, I, OH, NH2 and CH3;
Rd is selected from H and CH3.